Non‐serious adverse events · children with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · cirrhotic participants with large ascites treated by paracentesis
It is very uncertain whether other plasma expanders changes non‐serious adverse events compared with albumin (very low certainty).
1 finding from 1 review
Non‐serious adverse events · cirrhotic participants with large ascites treated by paracentesis
It is very uncertain whether plasma expanders changes non‐serious adverse events compared with no plasma expanders (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious adverse events · vascular dementia
1 finding from 1 review
Intervention not reported
Non‐serious adverse events · participants with β‐thalassaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · patients with covert or overt hepatic encephalopathy
It is very uncertain whether acetyl‐L‐carnitine changes non‐serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Non‐serious adverse events · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Non‐serious adverse events · adults with oesophageal varices
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · adults with cirrhosis and gastroesophageal varices
It is very uncertain whether carvedilol changes non‐serious adverse events compared with traditional, non‐selective beta‐blockers (very low certainty).
1 finding from 1 review
Non‐serious adverse events · people with venous leg ulcers
High frequency ultrasound probably leads to higher non‐serious adverse events compared with no ultrasound (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐serious adverse events · people with pressure ulcers
The intervention may leads to higher non‐serious adverse events (low certainty).
1 finding from 1 review
Non‐serious adverse events · patients with primary biliary cirrhosis.
It is very uncertain whether ursodeoxycholic acid changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious adverse events · Children aged less than 5 years
1 finding from 1 review
Total serious adverse events · patients with hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total serious adverse events · patients with hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found